Advertisement

Reactions Weekly

, Volume 1746, Issue 1, pp 50–50 | Cite as

Brigatinib

Development of an ALK-dominant resistance: case report
Case report
  • 19 Downloads

Reference

  1. Sakamoto MR, et al. Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clinical Lung Cancer 20: e133-e136, No. 2, Mar 2019. Available from: URL: http://doi.org/10.1016/j.cllc.2018.11.010 - USA

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations